Cargando…

Multilevel pharmacokinetics-driven modeling of metabolomics data

INTRODUCTION: Multilevel modeling is a quantitative statistical method to investigate variability and relationships between variables of interest, taking into account population structure and dependencies. It can be used for prediction, data reduction and causal inference from experiments and observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Daghir-Wojtkowiak, Emilia, Wiczling, Paweł, Waszczuk-Jankowska, Małgorzata, Kaliszan, Roman, Markuszewski, Michał Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306155/
https://www.ncbi.nlm.nih.gov/pubmed/28255294
http://dx.doi.org/10.1007/s11306-017-1164-4
_version_ 1782507140505665536
author Daghir-Wojtkowiak, Emilia
Wiczling, Paweł
Waszczuk-Jankowska, Małgorzata
Kaliszan, Roman
Markuszewski, Michał Jan
author_facet Daghir-Wojtkowiak, Emilia
Wiczling, Paweł
Waszczuk-Jankowska, Małgorzata
Kaliszan, Roman
Markuszewski, Michał Jan
author_sort Daghir-Wojtkowiak, Emilia
collection PubMed
description INTRODUCTION: Multilevel modeling is a quantitative statistical method to investigate variability and relationships between variables of interest, taking into account population structure and dependencies. It can be used for prediction, data reduction and causal inference from experiments and observational studies allowing for more efficient elucidation of knowledge. OBJECTIVES: In this study we introduced the concept of multilevel pharmacokinetics (PK)-driven modelling for large-sample, unbalanced and unadjusted metabolomics data comprising nucleoside and creatinine concentration measurements in urine of healthy and cancer patients. METHODS: A Bayesian multilevel model was proposed to describe the nucleoside and creatinine concentration ratio considering age, sex and health status as covariates. The predictive performance of the proposed model was summarized via area under the ROC, sensitivity and specificity using external validation. RESULTS: Cancer was associated with an increase in methylthioadenosine/creatinine excretion rate by a factor of 1.42 (1.09–2.03) which constituted the highest increase among all nucleosides. Age influenced nucleosides/creatinine excretion rates for all nucleosides in the same direction which was likely caused by a decrease in creatinine clearance with age. There was a small evidence of sex-related differences for methylthioadenosine. The individual a posteriori prediction of patient classification as area under the ROC with 5th and 95th percentile was 0.57(0.5–0.67) with sensitivity and specificity of 0.59(0.42–0.76) and 0.57(0.45–0.7), respectively suggesting limited usefulness of 13 nucleosides/creatinine urine concentration measurements in predicting disease in this population. CONCLUSION: Bayesian multilevel pharmacokinetics-driven modeling in metabolomics may be useful in understanding the data and may constitute a new tool for searching towards potential candidates of disease indicators. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-017-1164-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5306155
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-53061552017-02-28 Multilevel pharmacokinetics-driven modeling of metabolomics data Daghir-Wojtkowiak, Emilia Wiczling, Paweł Waszczuk-Jankowska, Małgorzata Kaliszan, Roman Markuszewski, Michał Jan Metabolomics Original Article INTRODUCTION: Multilevel modeling is a quantitative statistical method to investigate variability and relationships between variables of interest, taking into account population structure and dependencies. It can be used for prediction, data reduction and causal inference from experiments and observational studies allowing for more efficient elucidation of knowledge. OBJECTIVES: In this study we introduced the concept of multilevel pharmacokinetics (PK)-driven modelling for large-sample, unbalanced and unadjusted metabolomics data comprising nucleoside and creatinine concentration measurements in urine of healthy and cancer patients. METHODS: A Bayesian multilevel model was proposed to describe the nucleoside and creatinine concentration ratio considering age, sex and health status as covariates. The predictive performance of the proposed model was summarized via area under the ROC, sensitivity and specificity using external validation. RESULTS: Cancer was associated with an increase in methylthioadenosine/creatinine excretion rate by a factor of 1.42 (1.09–2.03) which constituted the highest increase among all nucleosides. Age influenced nucleosides/creatinine excretion rates for all nucleosides in the same direction which was likely caused by a decrease in creatinine clearance with age. There was a small evidence of sex-related differences for methylthioadenosine. The individual a posteriori prediction of patient classification as area under the ROC with 5th and 95th percentile was 0.57(0.5–0.67) with sensitivity and specificity of 0.59(0.42–0.76) and 0.57(0.45–0.7), respectively suggesting limited usefulness of 13 nucleosides/creatinine urine concentration measurements in predicting disease in this population. CONCLUSION: Bayesian multilevel pharmacokinetics-driven modeling in metabolomics may be useful in understanding the data and may constitute a new tool for searching towards potential candidates of disease indicators. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-017-1164-4) contains supplementary material, which is available to authorized users. Springer US 2017-02-08 2017 /pmc/articles/PMC5306155/ /pubmed/28255294 http://dx.doi.org/10.1007/s11306-017-1164-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Daghir-Wojtkowiak, Emilia
Wiczling, Paweł
Waszczuk-Jankowska, Małgorzata
Kaliszan, Roman
Markuszewski, Michał Jan
Multilevel pharmacokinetics-driven modeling of metabolomics data
title Multilevel pharmacokinetics-driven modeling of metabolomics data
title_full Multilevel pharmacokinetics-driven modeling of metabolomics data
title_fullStr Multilevel pharmacokinetics-driven modeling of metabolomics data
title_full_unstemmed Multilevel pharmacokinetics-driven modeling of metabolomics data
title_short Multilevel pharmacokinetics-driven modeling of metabolomics data
title_sort multilevel pharmacokinetics-driven modeling of metabolomics data
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306155/
https://www.ncbi.nlm.nih.gov/pubmed/28255294
http://dx.doi.org/10.1007/s11306-017-1164-4
work_keys_str_mv AT daghirwojtkowiakemilia multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata
AT wiczlingpaweł multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata
AT waszczukjankowskamałgorzata multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata
AT kaliszanroman multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata
AT markuszewskimichałjan multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata